AZ got past FluMist's efficacy woes, but now it's plagued by production problems

Officials recommended against AstraZeneca's FluMist for two years, but now the company has run into a different problem. Thanks to low production yields, AZ will limit FluMist supplies this season to a tiny fraction of the overall market, a spokeswoman said.